Hyundai Bio Receives Approval for Phase 2 Clinical Trial of Oral COVID-19 Treatment
[Asia Economy Reporter Chunhee Lee] Hyundai Bio's oral COVID-19 treatment has received approval for its Phase 2 clinical trial.
On the 17th, Hyundai Bio announced that its oral antiviral drug for COVID-19, 'CP-COV03,' received Phase 2 clinical trial approval from the Ministry of Food and Drug Safety on the 16th.
CP-COV03 contains niclosamide, a compound previously used as an anthelmintic. Niclosamide has been expected to show high antiviral efficacy against the COVID-19 virus. However, due to its low absorption rate and short half-life, it has been considered difficult to use as an antiviral specifically for COVID-19 because of its low bioavailability. Hyundai Bio explained that it overcame these issues by combining the drug delivery system (DDS) technology of its parent company, C&Pharm.
Unlike existing 'virus-targeting' antivirals that inhibit viral replication, CP-COV03 works by eliminating viruses that have invaded the host cells, resulting in rapid effectiveness. It is also free from drug resistance and is effective not only against the original Wuhan strain of COVID-19 but also variants such as Delta and Omicron, as well as other viruses.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This clinical trial will be conducted at Bestian Hospital with 300 patients. Hyundai Bio stated that after Phase 2, it plans to increase the number of participants from the original 120 to 300 and to integrate Phase 2a and 2b trials to apply for emergency use authorization.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
